BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29303707)

  • 21. Effectiveness of treatment with biologic- and disease-modifying antirheumatic drugs in rheumatoid arthritis patients in Colombia.
    Machado-Alba JE; Ruiz AF; Machado-Duque ME
    Int J Clin Pract; 2016 Jun; 70(6):506-11. PubMed ID: 27238964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.
    Bonafede M; Johnson BH; Tang DH; Shah N; Harrison DJ; Collier DH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1656-63. PubMed ID: 26097194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH; Whelton A
    Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case-control study on the association between rheumatoid arthritis and bladder pain syndrome/interstitial cystitis.
    Keller JJ; Liu SP; Lin HC
    Neurourol Urodyn; 2013 Sep; 32(7):980-5. PubMed ID: 23129416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.
    Nordström DC; Konttinen L; Korpela M; Tiippana-Kinnunen T; Eklund K; Forsberg S; Ilva K; Kaipiainen-Seppänen O; Malmi T; Ylä-Kerttula T; Honkanen V
    Rheumatol Int; 2006 Jun; 26(8):741-8. PubMed ID: 16205925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Temporomandibular Disorders in Rheumatoid Arthritis and Associated Risk Factors: A Nationwide Study in Taiwan.
    Lin CY; Chung CH; Chu HY; Chen LC; Tu KH; Tsao CH; Wu YT; Chien WC
    J Oral Facial Pain Headache; 2017 Fall; 31(4):e29-e36. PubMed ID: 29073669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.
    Liao TL; Lin CH; Chen HH; Chen YM; Lin CC; Chen DY
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of skin cancer in patients with pterygium: a nationwide population-based cohort study in Taiwan.
    Yu HC; Lin CL; Chen ZT; Hu FR; Sung FC; Wang IJ
    Ocul Surf; 2014 Jan; 12(1):69-76. PubMed ID: 24439048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DMARD use is associated with a higher risk of dementia in patients with rheumatoid arthritis: A propensity score-matched case-control study.
    Chou MH; Wang JY; Lin CL; Chung WS
    Toxicol Appl Pharmacol; 2017 Nov; 334():217-222. PubMed ID: 28927738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
    Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.
    Tam HW; Chen CM; Leong PY; Chen CH; Li YC; Wang YH; Lin LC; Chiou JY; Wei JC
    Int J Rheum Dis; 2018 Aug; 21(8):1591-1599. PubMed ID: 29372595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis.
    Suissa S; Ernst P; Hudson M; Bitton A; Kezouh A
    Am J Med; 2004 Jul; 117(2):87-92. PubMed ID: 15234643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
    Koyama Y; Shiraishi H; Ohta T; Uchino A
    Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
    Edwards CJ; Cooper C; Fisher D; Field M; van Staa TP; Arden NK
    Arthritis Rheum; 2007 Oct; 57(7):1151-7. PubMed ID: 17907232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.
    Solomon DH; Kremer JM; Fisher M; Curtis JR; Furer V; Harrold LR; Hochberg MC; Reed G; Tsao P; Greenberg JD
    Semin Arthritis Rheum; 2014 Feb; 43(4):489-97. PubMed ID: 24012043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.